TSE:CTX Crescita Therapeutics (CTX) Stock Forecast, Price & News C$0.63 -0.04 (-5.97%) (As of 09/29/2023 ET) Add Compare Share Share Today's RangeC$0.63▼C$0.6650-Day RangeC$0.63▼C$0.7352-Week RangeC$0.50▼C$0.79Volume3,970 shsAverage Volume22,583 shsMarket CapitalizationC$12.83 millionP/E Ratio12.60Dividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsHeadlinesSocial MediaProfileChartCompetitorsHeadlinesSocial Media About Crescita Therapeutics (TSE:CTX) StockCrescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. The company operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. It owns proprietary platform technologies, including Multiplexed Molecular Penetration Enhancers (MMPE) and DuraPeel for the development of topicals containing cannabis and hemp. The company's prescription products include Pliaglis, a topical local anesthetic cream that provides dermal analgesia on intact skin prior to superficial dermatological procedures; CTX-101, a Phase III topical formulation utilizing a corticosteroid in combination with MMPE technology to treat plaque psoriasis; CTX-102, a Phase I topical formulation utilizing MMPE technology to treat an undisclosed dermatological skin condition; and dermatology products in pre-clinical formulation utilizing MMPE technology for prescription treatments of skin diseases. Its non-prescription portfolio offers dermocosmetic products, such as facial creams, cleansers, exfoliants, masks, serums, and suncare to treat mild acne, aging, dehydration, pigmentation, sensitivity, and rosacea under the Laboratoire Dr Renaud brand; and provides medical aesthetics under Pro-Derm and Alyria brands, for non-invasive and minimally invasive procedures or skincare treatments. In addition, it distributes NCTF Boost 135 HA, a skin revitalization solution; Obagi Medical products; and ART FILLER, hyaluronic acid-based dermal fillers. The company has a commercialization license agreement with Cantabria Labs Inc.; and a development and commercialization license agreement with Taro Pharmaceuticals Inc. Crescita Therapeutics Inc. was incorporated in 2016 and is headquartered in Laval, Canada.Read More CTX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CTX Stock News HeadlinesSeptember 30, 2023 | theglobeandmail.comClosing Bell: Crescita Therapeutics Inc down on Friday (CTX)September 1, 2023 | theglobeandmail.comClosing Bell: Crescita Therapeutics Inc flat on Tuesday (CTX)September 30, 2023 | Stansberry Research (Ad)A 73-Year-Old Market Signal With 95% Accuracy Just FlashedThis signal has flashed just 24 times in the past 73 years – and it has signaled the exact moment to move your money with 95% accuracy. Now, it's flashing again. Discover where here.August 9, 2023 | finance.yahoo.comCrescita Reports Second Quarter 2023 ResultsAugust 6, 2023 | theglobeandmail.comClosing Bell: Crescita Therapeutics Inc flat on Monday (CTX)July 29, 2023 | theglobeandmail.comClosing Bell: Crescita Therapeutics Inc up on Friday (CTX)July 18, 2023 | theglobeandmail.comClosing Bell: Crescita Therapeutics Inc down on Monday (CTX)June 8, 2023 | finance.yahoo.comSubdued Growth No Barrier To Crescita Therapeutics Inc.'s (TSE:CTX) PriceSeptember 30, 2023 | Stansberry Research (Ad)A 73-Year-Old Market Signal With 95% Accuracy Just FlashedThis signal has flashed just 24 times in the past 73 years – and it has signaled the exact moment to move your money with 95% accuracy. Now, it's flashing again. Discover where here.June 1, 2023 | finance.yahoo.comCroma-Pharma: Launch of topical anaesthetic Pliaglis® in EuropeMay 11, 2023 | finance.yahoo.comCrescita Reports First Quarter 2023 ResultsApril 15, 2023 | theglobeandmail.comClosing Bell: Crescita Therapeutics Inc flat on Friday (CTX)April 12, 2023 | theglobeandmail.comClosing Bell: Crescita Therapeutics Inc up on Tuesday (CTX)April 11, 2023 | theglobeandmail.comClosing Bell: Crescita Therapeutics Inc flat on Thursday (CTX)April 8, 2023 | theglobeandmail.comClosing Bell: Crescita Therapeutics Inc flat on Wednesday (CTX)April 6, 2023 | theglobeandmail.comClosing Bell: Crescita Therapeutics Inc down on Wednesday (CTX)March 18, 2023 | seekingalpha.comCrescita Therapeutics GAAP EPS of C$0.06, revenue of C$6MMarch 15, 2023 | finanznachrichten.deCrescita Therapeutics Inc. Reports Q4 and Fiscal 2022 ResultsMarch 15, 2023 | msn.comCrescita Therapeutics GAAP EPS of $0.06, revenue of $6MMarch 15, 2023 | markets.businessinsider.comCrescita Therapeutics Q4 Profit Rises, But Revenues DeclineMarch 15, 2023 | finance.yahoo.comCrescita Reports Q4 and Fiscal 2022 ResultsNovember 16, 2022 | seekingalpha.comCTX:CA Crescita Therapeutics Inc.November 11, 2022 | finance.yahoo.comCrescita Therapeutics Third Quarter 2022 Earnings: EPS: CA$0.009 (vs CA$0.043 loss in 3Q 2021)November 9, 2022 | finance.yahoo.comCrescita Reports Third Quarter 2022 ResultsAugust 12, 2022 | seekingalpha.comCrescita Therapeutics GAAP EPS of C$0.00, revenue of C$6.51MAugust 10, 2022 | reuters.comCrescita Therapeutics IncAugust 10, 2022 | finance.yahoo.comCrescita Reports Second Quarter 2022 ResultsSee More Headlines Receive CTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Crescita Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeTSE Industry Drug Manufacturers—Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolTSE:CTX CUSIPN/A CIKN/A Webwww.crescitatherapeutics.com Phone+1-905-6734295FaxN/AEmployees62Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)C$0.05 Trailing P/E Ratio12.60 Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$1.06 million Net Margins3.75% Pretax MarginN/A Return on Equity4.04% Return on Assets0.56% Debt Debt-to-Equity Ratio6.86 Current Ratio4.08 Quick Ratio2.29 Sales & Book Value Annual SalesC$21.83 million Price / Sales0.59 Cash FlowC$0.53 per share Price / Cash Flow1.20 Book ValueC$1.01 per share Price / Book0.62Miscellaneous Outstanding Shares20,370,000Free FloatN/AMarket CapC$12.83 million OptionableNot Optionable Beta1.89 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Serge Verreault B.A.M.B.A., Pres, CEO & DirectorMr. Jose DaRocha C.A.CPA, Chief Financial OfficerMr. Francois LafortuneExec. VP & GMKey CompetitorsMedicureCVE:MPHWillow BiosciencesTSE:WLLWKhiron Life SciencesCVE:KHRNAleafia HealthTSE:AHDelta 9 CannabisTSE:DNView All Competitors CTX Stock - Frequently Asked Questions How have CTX shares performed in 2023? Crescita Therapeutics' stock was trading at C$0.66 at the beginning of 2023. Since then, CTX stock has decreased by 4.5% and is now trading at C$0.63. View the best growth stocks for 2023 here. What other stocks do shareholders of Crescita Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Crescita Therapeutics investors own include CBTX (CBTX), West Japan Railway (WJRYY), FAT Brands (FAT), Laredo Petroleum (LPI), Contango Oil & Gas (MCF), North American Construction Group (NOA), Spirit AeroSystems (SPR), Tesla (TSLA), Wells Fargo & Company (WFC) and Agellan Commercial Real Estate Invtmt TR (ACR.UN). What is Crescita Therapeutics' stock symbol? Crescita Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "CTX." How do I buy shares of Crescita Therapeutics? Shares of CTX stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. What is Crescita Therapeutics' stock price today? One share of CTX stock can currently be purchased for approximately C$0.63. How much money does Crescita Therapeutics make? Crescita Therapeutics (TSE:CTX) has a market capitalization of C$12.83 million and generates C$21.83 million in revenue each year. The company earns C$1.06 million in net income (profit) each year or C$0.05 on an earnings per share basis. How can I contact Crescita Therapeutics? Crescita Therapeutics' mailing address is 7560 Airport Rd Unit 10, MISSISSAUGA, ON L4T 4H4, Canada. The official website for the company is www.crescitatherapeutics.com. The company can be reached via phone at +1-905-6734295. This page (TSE:CTX) was last updated on 9/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crescita Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.